BRPI0415290A - uso terapêutico de variantes de quimiocina - Google Patents

uso terapêutico de variantes de quimiocina

Info

Publication number
BRPI0415290A
BRPI0415290A BRPI0415290-5A BRPI0415290A BRPI0415290A BR PI0415290 A BRPI0415290 A BR PI0415290A BR PI0415290 A BRPI0415290 A BR PI0415290A BR PI0415290 A BRPI0415290 A BR PI0415290A
Authority
BR
Brazil
Prior art keywords
variants
therapeutic use
chemokine variants
chemokine
inflammatory
Prior art date
Application number
BRPI0415290-5A
Other languages
English (en)
Inventor
Amanda Proudfoot
Jeffrey Shaw
Zoe Johnson
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BRPI0415290A publication Critical patent/BRPI0415290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)

Abstract

"USO TERAPêUTICO DE VARIANTES DE QUIMIOCINA". Os variantes de quimiocinas de formação de homodímero, tal como CCL2 humano, tendo uma substituição de aminoácido única na interface de dimerização que altera o padrão das ligações de hidrogênio e atuando como um monómero obrigatório, podem antagonizar as quimiocinas naturais e têm atividade antiinflamatória in vivo. Esses variantes podem ser empregados como ingrediente ativo em composições farmacêuticas para o tratamento de doenças inflamatórias, autoimunes ou infecciosas.
BRPI0415290-5A 2003-10-16 2004-10-18 uso terapêutico de variantes de quimiocina BRPI0415290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078308 2003-10-16
PCT/EP2004/052572 WO2005037305A1 (en) 2003-10-16 2004-10-18 Therapeutic uses of chemokine variants

Publications (1)

Publication Number Publication Date
BRPI0415290A true BRPI0415290A (pt) 2006-12-19

Family

ID=34442986

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415290-5A BRPI0415290A (pt) 2003-10-16 2004-10-18 uso terapêutico de variantes de quimiocina

Country Status (16)

Country Link
US (1) US7740833B2 (pt)
EP (1) EP1673103A1 (pt)
JP (1) JP2007510403A (pt)
KR (1) KR20070008510A (pt)
CN (1) CN1867352A (pt)
AR (1) AR046594A1 (pt)
AU (1) AU2004281552B2 (pt)
BR (1) BRPI0415290A (pt)
CA (1) CA2536082A1 (pt)
EA (1) EA009414B1 (pt)
IL (1) IL175020A0 (pt)
MX (1) MXPA06003695A (pt)
NO (1) NO20062109L (pt)
UA (1) UA91820C2 (pt)
WO (1) WO2005037305A1 (pt)
ZA (1) ZA200601900B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
EP2007815A2 (en) * 2006-03-31 2008-12-31 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
WO2007148317A1 (en) * 2006-06-21 2007-12-27 Compugen Ltd. Mcp-1 splice variants and methods of using same
ES2434039T3 (es) * 2006-07-24 2013-12-13 Yeda Research And Development Co. Ltd. Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
JP2012516143A (ja) * 2009-01-30 2012-07-19 プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト グリコサミノグリカンを拮抗するｍｃｐ−１突然変異体およびその使用方法
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US8796422B2 (en) * 2011-06-01 2014-08-05 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
CN103857406B (zh) * 2011-06-01 2018-02-23 吉安特科技公司 趋化因子‑免疫球蛋白融合多肽、组合物及其制备和使用方法
US9249204B2 (en) 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
WO2012172342A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating multiple sclerosis
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
EP3253797A4 (en) * 2015-02-03 2018-10-03 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR102066149B1 (ko) * 2018-08-17 2020-01-14 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 임신촉진용 조성물
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT719331E (pt) * 1993-09-14 2007-01-31 Imp Innovations Ltd Eotaxina-citocina quimiotáctica de eosinófilos
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998031794A1 (fr) * 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
DK1200479T3 (da) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
DE60224822T2 (de) * 2001-10-19 2009-01-22 Zymogenetics, Inc., Seattle Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
EP1497423A4 (en) * 2002-03-26 2006-05-24 Centocor Inc MUTANT MCP-1 PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
AU2003240765A1 (en) * 2002-04-10 2003-10-20 Applied Research Systems Ars Holding N.V. Novel antagonists of mcp proteins
EP2007815A2 (en) * 2006-03-31 2008-12-31 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors

Also Published As

Publication number Publication date
ZA200601900B (en) 2007-07-25
EP1673103A1 (en) 2006-06-28
NO20062109L (no) 2006-05-11
CN1867352A (zh) 2006-11-22
AU2004281552A1 (en) 2005-04-28
JP2007510403A (ja) 2007-04-26
UA91820C2 (ru) 2010-09-10
US7740833B2 (en) 2010-06-22
AU2004281552B2 (en) 2009-10-22
IL175020A0 (en) 2006-08-20
AR046594A1 (es) 2005-12-14
EA009414B1 (ru) 2007-12-28
US20070280958A1 (en) 2007-12-06
CA2536082A1 (en) 2005-04-28
KR20070008510A (ko) 2007-01-17
WO2005037305A1 (en) 2005-04-28
EA200600782A1 (ru) 2006-08-25
MXPA06003695A (es) 2006-06-20

Similar Documents

Publication Publication Date Title
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DK1079806T3 (da) Præparater til påföringen af antiinflammatoriske, især antiseptiske midler og/eller midler, der fremmer helingen af sår, til de övre luftveje og/eller öret
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DK1071439T3 (da) Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis
NO20050162L (no) Nye antagonister av CXCR3-bindene CXC-kjemokiner
DK0832081T3 (da) Bicykliske-aromatiske forbindelser
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
BR0309238A (pt) Antagonistas de proteìnas mcp
BR9702144A (pt) Compostos propinil biaromáticos composição farmacêutica composição cosmética e utilização de uma composição cosmética
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
DE60036199D1 (de) Proteaseresistente flint-analoge
WO1999014322A3 (en) Allelic variant of human stat3
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco
RU155639U1 (ru) Несъемно-разборный мостовидный протез
BR0208364A (pt) Novos peptìdeos ligantes das integrinas de leucócitos e uso dos mesmos
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
BRPI0400359A (pt) Uso de um fucano, composição farmacêutica, e, método para preparar um medicamento capaz de reduzir sintomas associados com pelo menos uma dentre aderência, artrite, e psorìase em um paciente humano
YU17703A (sh) Nova farmaceutska kompozicija za primenu na koži
ECSP045431A (es) Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
ECSP993107A (es) Metodo para incrementar la resistencia y dureza del hueso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.